A French company launches a home-based PCR test
A French company launches a home-based PCR test. Less invasive than the classic sampling method, the PCR proposed by Eurofins is about to be launched in Europe. These screening kits will not be salivary and from his home.
“Test, alert, protect” is the strategy adopted by the government in response to the resurgence of the epidemic on French territory. The PCR test, performed in a laboratory or pharmacy, has become the standard when it comes to detecting the coronavirus in patients. But this practice, while effective, has some drawbacks. First, because it is quite unpleasant and above all because it is not suitable for all patients. This is particularly the case for young children, the elderly, and even people suffering from serious deviations of the nasal septum. To allow easier detection of the virus, a Nantes company has developed a home screening kit. Delivered directly to the patient, it contains a small saline solution with which to gargle for 5 to 10 seconds. The user must then spit out the liquid in a dedicated tube and place his sample in an envelope. This will then be collected by a carrier the next day. According to Eurofins, the results will be available online 24 hours after receipt of the package.
If it has already been authorized in the United States by the FDA, this “non-invasive” test method has yet to await regulatory authorizations to be marketed in Europe. In a press release, relayed by LCI, the company explains announces that it “will apply for regulatory authorizations to market similar tests in the United Kingdom, France, Belgium, the Netherlands, Sweden, and other countries. “ Eurofins believes that ” this product can significantly expand access to testing. » This European version of the test is already available online in Germany and is sold for 79 euros. In the United States, the test is paid for by Medicare, Medicaid, and commercial insurance. However, nothing indicates whether it will be part of the tests reimbursed by social security in France. She also claims that these tests will be able to detect the variation in the virus seen in the UK. It will also give access to part of its sequencing capacities to European national health authorities who could not identify this new strain.